Lymphoma in inflammatory bowel disease and treatment decisions.
Lymphoma in inflammatory bowel disease and treatment decisions.
复制标题
炎症性肠病中的淋巴瘤和治疗决策。
DOI：
10.1038/ajg.2011.479
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Bewtra,Meenakshi
中科院分区：
文献类型：
--
作者：
Bewtra,Meenakshi
淋巴瘤，特别是非霍奇金淋巴瘤的风险是与炎症性肠病（IBD）治疗相关的一个重要问题。几乎所有 IBD 免疫调节疗法都存在淋巴瘤风险，因此在开始治疗前与患者进行讨论非常重要。然而，将风险置于 IBD 患者能够适当理解的环境中也很重要。这些药物的相对风险可能看起来很大，而相比之下，绝对风险可能相当低。此外，了解上述免疫调节治疗的风险——特别是持续活动性疾病和/或持续使用皮质类固醇——可以为患者和医生进行适当的风险效益讨论。
The risk of lymphoma, particularly non-Hodgkin’s lymphoma, is an important concern associated with therapy for inflammatory bowel disease (IBD). Lymphoma risks have been described for nearly all immunomodulatory therapies for IBD, and it is therefore important to have discussions with patients before initiating therapy. However, it is also important to put risks into contexts that IBD patients can appropriately appreciate. Relative risks can appear large for these medications, while, by contrast, the absolute risk may be quite low. Additionally, understanding the risks of foregoing immunomodulatory therapy—specifically, continued active disease and/or continued corticosteroid use—can frame an appropriate risk–benefit discussion for both patients and physicians.